NewAmsterdam Pharma Company NAMS Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's total liabilities?
- NewAmsterdam Pharma Company (NAMS) reported total liabilities of $67.42M in Q1 2026.
- How has NewAmsterdam Pharma Company's total liabilities changed year-over-year?
- NewAmsterdam Pharma Company's total liabilities increased by 64.2% year-over-year, from $41.05M to $67.42M.
- What is the long-term trend for NewAmsterdam Pharma Company's total liabilities?
- Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's total liabilities has grown at a 21.0% compound annual growth rate (CAGR), from $48.43M to $85.85M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.